MATTHEW BRIGMON: Open Payments
NPI 1609475284 · MYRTLE BEACH, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,665 in 124 payments from 20 companies in 2025. Trend: 2023 $997 · 2024 $2,138 · 2025 $2,665
Food & beverage: $2,665
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 33 | $677 |
| GlaxoSmithKline, LLC. | 23 | $399 |
| GENZYME CORPORATION | 8 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $197 |
| Insmed, Inc. | 7 | $185 |
| Merck Sharp & Dohme LLC | 8 | $149 |
| Regeneron Healthcare Solutions, Inc. | 4 | $128 |
| Verona Pharma, Inc. | 6 | $123 |
| Viatris Specialty LLC | 7 | $118 |
| United Therapeutics Corporation | 4 | $117 |
Products named: DUPIXENT, FASENRA, NUCALA, TEZSPIRE, Arikayce, GLASSIA, Ohtuvayre, TRELEGY ELLIPTA.
Industry payments across SC — which companies pay providers there.
